Instil Bio's Promising Clinical Trial Results for ImmuneOnco Biopharmaceuticals' IMM2510/AXN-2510

Instil Bio (TIL) reported positive preliminary results from a Phase 2 study of IMM2510/AXN-2510 for advanced non-small cell lung cancer in China. The safety profile was favorable with no dose-limiting toxicities or fatalities. The company has a market capitalization of $177.18 million and is focused on developing cell therapy pipelines for cancer treatment. Instil Bio's financial health is mixed, with ongoing losses and moderate debt levels. Its business performance is characterized by its innovative cancer therapies, and valuation metrics reflect its developmental stage.

Instil Bio Inc. (TIL), a clinical-stage biopharmaceutical company, has reported positive preliminary results from a Phase 2 study of its IMM2510/AXN-2510 therapy for advanced non-small cell lung cancer (NSCLC) in China. The study, conducted by ImmuneOnco Biopharmaceuticals, showed promising efficacy and a favorable safety profile.

The study, which included 33 patients, demonstrated a 62% overall response rate, with notable efficacy in squamous NSCLC, where 80% of patients responded. In non-squamous NSCLC, the response rate was 46% [1]. The therapy was well-tolerated, with no dose-limiting toxicities or fatalities observed. The most common serious side effects were hematologic, while adverse events typically associated with VEGF inhibition were uncommon and generally low-grade [1].

The favorable results of the study suggest that IMM2510/AXN-2510 has the potential to advance to Phase 3 trials and become a new standard of care for front-line NSCLC. The company plans to initiate a US Phase 1 clinical trial before the end of the year [2].

Instil Bio's stock jumped 5.5% in premarket trading following the announcement of the preliminary data [2]. The company, with a market capitalization of $177.18 million, is focused on developing innovative cell therapy pipelines for cancer treatment. However, its financial health is mixed, with ongoing losses and moderate debt levels.

References:
[1] https://ir.instilbio.com/news-releases/news-release-details/immuneonco-announced-preliminary-safety-efficacy-data-clinical
[2] https://www.investing.com/news/stock-market-news/instil-bio-stock-rises-after-positive-data-for-cancer-therapy-in-china-93CH-4163393